Entasis Therapeutics

73 articles about Entasis Therapeutics

• Entasis Therapeutics Announces Multiple Data Presentations at ECCMID 2019

  4/10/2019

  Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat serious drug-resistant infections, today announced multiple data presentations on ETX2514SUL and ETX0282CPDP as well as its preclinical non-beta-lactam PBP inhibitor (NBP) program at the 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), taking place April 13-16, 2019 in Amsterdam, Netherlands.

• Entasis Therapeutics Initiates Global Phase 3 Pivotal Trial of ETX2514SUL for Patients with Carbapenem-Resistant Acinetobacter Infections

  4/4/2019

  Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel antibacterials to treat serious drug-resistant infections, today announced the initiation of the ATTACK (AcinetobacterTreatment Trial Against Colistin) Phase 3 pivotal clinical trial to evaluate ETX2514SUL, a fixed-dose combination of its broad-spectrum β-lactamase inhibitor ETX2514 with sulbactam,

• Entasis Therapeutics Receives Positive Feedback from FDA End-of-Phase 2 Meeting for ETX2514SUL; Signs Rapid Diagnostic Agreement with bioMérieux

  2/6/2019

  Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding ETX2514SUL for the treatment of patients with pneumonia and bloodstream infections caused by carbapenem-resistantAcinetobacter baumannii

• 

  Novo Nordisk Investment Fund Backs Companies Developing Therapies Combatting Antimicrobial Resist...

  1/21/2019

  Novo Nordisk’s investment arm, Novo Holdings, invested a little more than $20 million in four different companies over the course of 2018 through its REPAIR Impact Fund. That $165 million fund was established last year to support companies developing therapies to combat antimicrobial resistance.

• Entasis Therapeutics to Present on ETX2514SUL at IDWeek 2018

  10/3/2018

  Entasis Therapeutics (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced an oral presentation at the Infectious Disease Society of America (IDSA) IDWeek™ 2018 taking place October 3 - 7, 2018 in San Francisco, California.

• 

  On the Heels of bluebird bio Collaboration, Gritstone Secures $100 Million in IPO

  9/28/2018

  Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.
• 

  A Look at 7 Upcoming and Recently Announced Biotech IPOs

  9/24/2018

  According to BioPharm Catalyst there were, or soon will be, 58 biopharma IPOs in 2018. And the trend doesn’t appear to be slowing. Here’s a look at five upcoming biotech IPOs.

• Entasis Therapeutics Announces Positive Topline Results from Phase 2 Trial of ETX2514SUL in Patients with Complicated Urinary Tract Infections including Acute Pyelonephritis

  8/14/2018

  ETX2514SUL was generally well tolerated

• Entasis Therapeutics Inc. Joins Antimicrobials Working Group

  7/2/2018

  The Antimicrobials Working Group (AWG) announced today the addition of Entasis Therapeutics Inc. (Entasis) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations.

• Entasis Therapeutics to Present Data on ETX2514 and ETX0282 at ASM Microbe 2018

  6/6/2018

  Presentations will include clinical and preclinical data on ETX2514

• Entasis Therapeutics Initiates Clinical Studies of the Oral Extended-Spectrum Beta-Lactamase Inhibitor ETX0282

  5/14/2018

  Entasis Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced initiation of a Phase 1 clinical trial of its novel oral beta-lactamase inhibitor ETX0282. ETX0282CPDP, the combination of ETX0282 with cefpodoxime, is being developed as an oral therapy for infections caused by multidrug-resistant (MDR) Gram-negative pathogens, including MDR and carbapenem-resistant Enterobacteriaceae (CRE).

• Entasis Therapeutics Appoints David C. Hastings to Board of Directors

  5/1/2018

  Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the appointment of David C. Hastings to the company’s Board of Directors.

• Entasis Therapeutics and Zai Lab Announce Exclusive License Agreement in Asia-Pacific and Global Strategic Development Collaboration for ETX2514

  4/25/2018

  Entasis Therapeutics Holdings Inc. announced an exclusive license agreement for ETX2514 in the Asia-Pacific region and a global strategic development collaboration.

• Entasis Receives Second CARB-X Award, Providing Up To $10.1 Million For Development Of Non-Beta-Lactam PBP Inhibitor Program

  10/12/2017

• Entasis Highlights Positive Phase I Data For ETX2514 At IDWeek 2017, Announces Plans To Advance Combination With Sulbactam (ETX2514SUL) Into Phase II Trials

  10/9/2017

• Entasis To Present Phase 1 Data On ETX2514 At IDWeek 2017

  9/28/2017

• Massachusetts' Entasis Snags $31.9 Million To Advance Anti-infective Therapeutic Portfolio

  9/5/2017

• Entasis And The Global Antibiotic Research & Development Partnership (GARDP) To Develop A New Treatment For Drug-Resistant Gonorrhea

  7/7/2017

• Entasis Publishes Data Highlighting The Potent And Differentiated Activity Of ETX2514 Combinations Against Drug Resistant Gram-Negative Bacteria Including Acinetobacter And Pseudomonas

  7/5/2017

• Entasis Presents Data On Third Drug Candidate, Etx0282, An Orally Available, Extended-Spectrum ?eta-Lactamase Inhibitor, At AAM Microbe 2017

  6/7/2017